Simonetto M, Rutrick S, LeMoss NM, Lansdale KN, Tagawa ST, Kamel H, Parikh N, Navi BB.
2022.
Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis.. J Stroke Cerebrovasc Dis. 31(3):106297.
Cho J, Nguyen TD, Huang W, Sweeney EM, Luo X, Kovanlikaya I, Zhang S, Gillen KM, Spincemaille P, Gupta A et al..
2022.
Brain oxygen extraction fraction mapping in patients with multiple sclerosis.. J Cereb Blood Flow Metab. 42(2):338-348.
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA et al..
2022.
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.. Mult Scler Relat Disord. 68:104143.
De Michele M, Kahan J, Berto I, Schiavo OG, Iacobucci M, Toni D, Merkler AE.
2022.
Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination.. Circ Res. 130(8):1187-1203.
Zinger N, Ponath G, Sweeney E, Nguyen TD, Lo CHung, Diaz I, Dimov A, Teng L, Zexter L, Comunale J et al..
2022.
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions.. Neurol Neuroimmunol Neuroinflamm. 9(2)
Dimov AV, Nguyen TD, Spincemaille P, Sweeney EM, Zinger N, Kovanlikaya I, Kopell BH, Gauthier SA, Wang Y.
2022.
Global cerebrospinal fluid as a zero-reference regularization for brain quantitative susceptibility mapping.. J Neuroimaging. 32(1):141-147.
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ.
2022.
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.. CNS Drugs. 36(9):977-993.
Rúa SMHurtado, Kaunzner UW, Pandya S, Sweeney E, Tozlu C, Kuceyeski A, Nguyen TD, Gauthier SA.
2022.
Lesion features on magnetic resonance imaging discriminate multiple sclerosis patients.. Eur J Neurol. 29(1):237-246.